Navigation Links
Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
Date:10/25/2007

MTD in NSCLC Identified; Phase 2 Study Planned

WESTMINSTER, Colo., Oct. 25 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH), a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, today announced that results from three PDX studies were presented as posters during the 2007 AACR-NCI-EORTC conference held October 22-26, 2007 in San Francisco, California. The posters described the effects of PDX (pralatrexate) in patients with non-small cell lung cancer (NSCLC), in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and Hodgkin's disease, and in human cancer models in vivo and in vitro.

PDX in NSCLC (Phase 1)

The poster entitled "Phase 1 study of the antifolate pralatrexate when given with vitamin B12 and folic acid supplementation in patients with advanced non-small cell lung cancer (NSCLC)" presented results of this Phase 1 dose ranging study. In the study, a total of 22 patients with relapsed or refractory NSCLC were treated at doses of 150 to 325 mg/m2 of PDX. The maximum tolerated dose (MTD) was determined to be 270 mg/m2, which is twice that observed in a previous Phase 1 study in which PDX was administered without vitamin supplementation. Clinically significant radiologic responses were observed. Greater than 50% of patients (13/22) received two or more prior treatment regimens. Based on PDX clinical experience to date, the Company plans to initiate a randomized Phase 2 study of PDX in patients with NSCLC.

PDX in NHL (Phase 1/2)

The poster entitled "A Phase '2-1-2' Study of Two Different Doses and Schedules of Pralatrexate, A High Affinity Substrate for the Redu
'/>"/>

SOURCE Allos Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The TripleMaster PCR System for three different amplifications
2. Cloning Based on Efficient Three-Fragment Assembly DNA Ligation
3. Three Micron TSK-GEL ODS-100V Columns for High Throughput LCMS
4. Three finalists named for UW-Madison CIO
5. Three state businesses receive technology grants
6. Leading cancer institute to install three TomoTherapy systems
7. Waukesha considers wireless bids from three firms
8. Computerworld top 100 includes three Wisconsin CIOs
9. 30 days to success: Three simple steps to create your own international startup
10. Three firms get state tech development grants
11. Three more Wisconsin firms to present at venture forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... The report “Pharmacy Automation Systems ... and Labeling Systems, Table-top Counters) by End-user (Inpatient ... & Trends to 2019” analyzes and studies the ... America, Europe, Asia-Pacific, and the Rest of the ... 30 figures spread through 300 pages and in-depth ...
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
(Date:10/20/2014)...  GenVec, Inc. (NASDAQ: GNVC ) today announced ... its board of directors effective on October 24, 2014.   Dr. ... as its chairman from June 2006 to November 2013.  During ... Governance and Audit Committees of the board.  ... dedicated service to GenVec, and its stockholders," said Wayne ...
(Date:10/20/2014)... Rochelle, Virginia (PRWEB) October 20, 2014 ... of NDA Partners LLC, announced today that Ellen ... and legal support for the pharmaceutical industry, has ... and manager of its legal services practice. ... reports and expert witness and testimony, to top ...
Breaking Biology Technology:Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Zola P. Horovitz To Retire From GenVec Board 2NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2
... , , , BETHLEHEM, Pa., ... , (Logo: http://www.newscom.com/cgi-bin/prnh/200 8 1022 / ... two Lehigh Valley healthcare leaders, Good S h epherd Rehabilitation ... nc. (B. Braun), which are combining their knowledge, expertise and innovative technology ...
... , , , TUSTIN, ... today announced that it will release its financial results for the first ... EDT and will host a conference call and webcast to discuss the ... Peregrine,s senior management will discuss financial results for the first ...
... , , SEATTLE, Aug. 27 ... Company will hold an Analyst Day on Thursday, September 24, 2009 beginning ... audio webcast of the presentation will be accessible through the Investor Relations ... to listen to the live webcast, it will be archived on the ...
Cached Biology Technology:Two Lehigh Valley Healthcare Leaders Collaborate to Deliver Safer, High-Quality Care to the Community 2Two Lehigh Valley Healthcare Leaders Collaborate to Deliver Safer, High-Quality Care to the Community 3Two Lehigh Valley Healthcare Leaders Collaborate to Deliver Safer, High-Quality Care to the Community 4Peregrine Pharmaceuticals to Report First Quarter FY 2010 Financial Results 2
(Date:10/22/2014)... BEDFORD, Mass., Oct. 21, 2014 Aware, Inc. (NASDAQ: ... and services, today reported financial results for its third quarter ... quarter of 2014 was $6.0 million, an increase of 40% ... Operating income in the third quarter of 2014 was $4.1 ... 2013. Higher operating income in the current three month period ...
(Date:10/18/2014)... referred for evaluation of suspected genetic conditions, whole-exome ... percent, including detection of a number of rare ... according to a study appearing in JAMA ... with the American Society of Human Genetics annual ... coding regions of thousands of genes simultaneously using ...
(Date:10/17/2014)... German . ... in order to reproduce? And why are there two sexes ... latest issue of the research journal Molecular Human Reproduction ... Ramm from Bielefeld University Bielefeld has compiled this special issue ... a female to copulate with several males in quick succession ...
Breaking Biology News(10 mins):Aware, Inc. Reports Third Quarter 2014 Financial Results 2Aware, Inc. Reports Third Quarter 2014 Financial Results 3Aware, Inc. Reports Third Quarter 2014 Financial Results 4Aware, Inc. Reports Third Quarter 2014 Financial Results 5Aware, Inc. Reports Third Quarter 2014 Financial Results 6Aware, Inc. Reports Third Quarter 2014 Financial Results 7Whole-exome sequencing shows potential as diagnostic tool 2Sperm wars 2
... for spiders, it can be a matter of life or ... potentially cannibalistic females that he is a suitable mate and ... Cincinnati shows that male wolf spiders are "leaving" little to ... mate. To improve the chances of the right message ...
... A new company has been launched to commercialise ... Strathclyde in Glasgow, for tackling bacterial infection and ... Phage Limited has been established to develop products ... prevention of infection and bacterial contamination in medicine, ...
... standard intestinal examination for diagnosing and monitoring Crohn,s disease. It ... with a camera is passed into the large intestine. MRI ... the course of the disease and how it is responding ... the academic world to develop an objective, quantitative method for ...
Cached Biology News:Spiders adjust courtship signals for maximum effect 2Spiders adjust courtship signals for maximum effect 3Spin-out to apply new technology for tackling infection 2Spin-out to apply new technology for tackling infection 3EU grant for better monitoring of Crohn's disease using MRI 2EU grant for better monitoring of Crohn's disease using MRI 3
... The active ingredient in Molecular Probes. ... appears to act as a free ... emission. Our original SlowFade formulation (S-2828) ... rate of fluorescein to almost zero ...
... IRsolution software provides quick and easy ... functions with Windows-based control. The software ... and FDA 21 CFR Part 11 regulations, ... of measurement. IRsolutions versatility enables use ...
b6-2A12...
... reagents for immune complex disruption (ICD) of ... using a combination of low pH and ... transferred to microplate wells which are coated ... to HIV-1 p24. The immobilized monoclonal antibody ...
Biology Products: